Membrane and intracellular progesterone receptors as determinants of the

项目摘要(见说明)：在第一个供资阶段。项目1侧重于黄体酮受体在黄体酮(P4)细胞保护作用中的作用。尤其是。项目1挑战了经典孕激素受体(PR)是P4‘S脑保护作用的主要中介这一教条，提出最近描述的膜相关孕激素受体可能同样重要。主要的发现包括观察到经典的PR和膜相关的孕激素受体，特别是PgrmCL，确实共同调节关键的细胞保护介质，包括ERK/MAPK通路的效应者(如ERK1/2和ERK5)和BDNF。在这个项目的继续中，我们建议应用这一知识来理解是否1)激素剥夺后或随着年龄的增长，P4‘S对神经保护和细胞保护的关键介质的作用保持了一个有限的时期(即治疗窗口)，以及2)PR和PgrmCL的相对丰富是否预测了P4的持续保护作用。此外，我们将确定孕激素受体表达的特定模式是否可以预测P4是补充还是拮抗雌激素的保护作用。我们的假设是，经典PR和膜孕酮受体PgrmCL的联合表达是维持大脑对P4的反应性所必需的。此外，我们认为，这两种受体的相对丰度也将预测P4是否补充雌激素的保护程序，或者是否拮抗雌激素的作用。这些假说将在细胞模型中进行测试，在细胞模型中，PR和PgrmCL的相对水平可以被操纵(药理学或使用分子工具)，以及在类固醇剥夺的动物模型中(卵巢切除)，最后，转化为卵巢切除的人类模型(即外科更年期)。虽然雌激素的有益作用随着卵巢切除后持续时间的增加而丧失已有描述，但对P4的反应尚不清楚。因此，本文提出的研究将通过确定哪些黄体酮受体是P4‘S保护效应的关键决定因素来揭示“治疗窗口”之谜的关键部分，重要的是，可能为如何扩大治疗窗口提供独特的见解(即，通过调节特定的黄体酮受体)。与项目2和项目3中提出的研究一起，我们期望这一研究项目将促进我们对雌激素和黄体酮治疗机会的“关键窗口”的神经生物学基础的理解，这是仅靠项目1无法实现的目标。

PROJECT SUMMARY (See instructions): During the first period of funding. Project 1 focused on addressing the role of progesterone receptors in mediating the cytoprotective effects of progesterone (P4). In particular. Project 1 challenged the dogma that classical progesterone receptors (PR) are the principal mediators of P4's protective effects in the brain by suggesting that recently described membrane-associated progesterone receptors may be equally important. Major findings included the observation that indeed both the classical PR and membrane-associated progesterone receptors, particularly Pgrmcl, cooperate to regulate key cytoprotective mediators, including effectors of the ERK/MAPK pathway (such as ERK1/2 and ERK5) and BDNF. In the continuation of this project, we propose to apply this knowledge to understand whether 1) there is a finite period (i.e., therapeutic window) following steroid hormone deprivation, or with age, where P4's effects on neuroprotection and key mediators of cytoprotection are maintained, and 2) if the relative abundance of PR and Pgrmcl predict sustained protective effects of P4. Further, we will determine whether specific patterns of progesterone receptor expression predict whether P4 complements or antagonizes estrogen's protective effects. Our hypothesis states that the combined expression of the classical PR and the membrane progesterone receptor, Pgrmcl, is required to maintain responsiveness of the brain to P4. Further, we propose that the relative abundance of these two receptors will also predict whether P4 complements estrogen's protective program or whether it antagonizes estrogen's effects. These hypotheses will be tested in cellular models, where the relative levels of PR and Pgrmcl can be manipulated (pharmacologically or using molecular tools), as well as in an animal model of steroid deprivation (ovariectomy), and finally, translated to a human model of ovariectomy (i.e., the surgical menopause). While the loss of estrogen's beneficial effects with increasing post-ovariectomy duration has been described, nothing is known with respect to the response to P4. Thus, the studies proposed herein will reveal a key piece of the "therapeutic window" puzzle by defining which progesterone receptors are critical determinants of P4's protective effects and importantly, may offer unique insight into how the therapeutic window may be expanded (i.e., through regulation of specific progesterone receptors). Together with the studies proposed in Projects 2 and 3, we expect this program of research to advance our understanding of the neurobiological basis of the "critical window" of therapeutic opportunity for estrogen and progesterone, a goal that could not be achieved by Project 1 alone.